Design and synthesis of new pyranoxanthenones bearing a nitro group or an aminosubstituted side chain on the pyran ring. Evaluation of their growth inhibitory activity in breast cancer cells

被引:23
作者
Kolokythas, George
Kostakis, Ioannis K.
Pouli, Nicole
Marakos, Panagiotis
Kousidou, Olga Ch.
Tzanakakis, George N.
Karamanos, Nikos K.
机构
[1] Univ Athens, Dept Pharm, Div Pharmaceut Chem, GR-15771 Athens, Greece
[2] Univ Crete, Sch Med, Dept Hist, Iraklion 71110, Greece
[3] Univ Patras, Dept Chem, Biochem Lab, GR-26110 Patras, Greece
关键词
1,2-dihydropyrano[2,3-c]xanthenones; breast cancer cells; growth inhibitory effect;
D O I
10.1016/j.ejmech.2006.10.018
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Some new 2,6-disubstituted pyrano- and 1,2-dihydropyrano[2,3-c]xanthen-7-ones have been synthesized and their antiproliferative activity has been evaluated against MDA-MB-231 breast cancer cells. The antiproliferative activity evaluation of the compounds provided evidence that a dimethylamino substituted side chain and the presence of 1,2 double bond play a key role in cell growth inhibition. Among the tested derivatives the 6-dimethylaminoethylamino-2-nitropyranoxanthenone analogue possessed a significant inhibitory effect in a wide range of concentrations. (c) 2006 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:307 / 319
页数:13
相关论文
共 21 条
[1]   DNA recognition by two mitoxantrone analogues: Influence of the hydroxyl groups [J].
Bailly, C ;
Routier, S ;
Bernier, JL ;
Waring, MJ .
FEBS LETTERS, 1996, 379 (03) :269-272
[2]   The role of pixantrone in the treatment of non-Hodgkin's lymphoma [J].
Borchmann, P ;
Schnell, R .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (08) :1055-1061
[3]  
Borchmann P, 2003, IDRUGS, V6, P486
[4]   Intercalators as anticancer drugs [J].
Braña, MF ;
Cacho, M ;
Gradillas, A ;
de Pascual-Teresa, B ;
Ramos, A .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (17) :1745-1780
[5]   SYNTHESIS, MOLECULAR MODELING, DNA-BINDING, AND ANTITUMOR PROPERTIES OF SOME SUBSTITUTED AMIDOANTHRAQUINONES [J].
COLLIER, DA ;
NEIDLE, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (04) :847-857
[6]  
Costes N, 2003, ONCOL RES, V13, P191
[7]   A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly [J].
Dawson, LK ;
Jodrell, DI ;
Bowman, A ;
Rye, R ;
Byrne, B ;
Bernareggi, A ;
Camboni, G .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) :2353-2359
[8]  
DORR RT, 1989, CANCER RES, V49, P340
[9]  
Elomri A, 1996, CHEM PHARM BULL, V44, P2165
[10]  
Ghirtis K, 2000, HETEROCYCLES, V53, P93